BioCentury
ARTICLE | Clinical News

Vapendavir: Ph IIb SPIRITUS data

February 23, 2017 2:13 AM UTC

Top-line data from the double-blind, international Phase IIb SPIRITUS trial in 168 evaluable patients ages 18-70 with moderate to severe asthma and laboratory-confirmed HRV infection showed that twice...

BCIQ Company Profiles

Aviragen Therapeutics Inc.

BCIQ Target Profiles

HRV capsid